Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: LTI-03 in Idiopathic Pulmonary Fibrosis
NCT06968845Phase 2Recruiting
- Sponsor
- Rein Therapeutics
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Modified Peptides, Native Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Rein Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at 24 weeks. Started Feb 2026; status: recruiting.
02
Drugs
LTI-03
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06968845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968845.